A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SC PFS IN ADULT PARTICIPANTS WITH GRAVES’ DISEASE INADEQUATELY CONTROLLED WITH ANTITHYROID DRUGS

Registry ID

ARGX-113-25-GRD-3001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ARGENX BV

Start date

2026-06-25

Last update

2026-05-01

Conditions

• GRAVE'S DISEASE

Related clinical trials

• AN OPEN-LABEL PHASE 2 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RILZABRUTINIB IN ADULT PARTICIPANTS WITH GRAVES' DISEASE

View on source registry